Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aqualibra is a fixed-dose herbal medicinal product composed of three standardized plant extracts: restharrow root (*Ononis spinosa*), Java tea (*Orthosiphon aristatus*), and goldenrod herb (*Solidago virgaurea*). Formulated as film-coated tablets, it is primarily indicated for the treatment of acute lower uncomplicated urinary tract infections (UTIs) in women. The combination acts through a multi-target mechanism, providing aquaretic (diuretic), anti-inflammatory, and antimicrobial effects. It is designed to flush the urinary tract, prevent bacterial adhesion to the bladder wall, and alleviate symptomatic pain and inflammation. Clinical studies, including randomized double-blind trials (e.g., NCT04032574), have evaluated its efficacy as a non-antibiotic alternative for managing symptomatic UTIs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ononidis radix extract + orthosiphonis folium extract + solidaginis herba extract.